Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PANTOTHENIC ACID”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,567 records · Page 87Linked to original sources
PubMed1990

[GELUM oral-rd: blood pH regulator and oxygen activator. Documentation No.27].

GELUM oral-rd contains a potassium iron phosphate-potassium iron citrate complex, lactic acid and vitamins. It is recommended in oxygen deficiency states, tissue and tumour diseases and more recently as an adjunct to tumour therapy. The recommended dosage is 20 drops three times daily, to be taken for 5 to 10 years following cancer surgery. No side effects are stated. The daily cost of treatment is DM - .60 to DM 1.35. Manufacturer: Laboratorium pharmazeutischer Erzeugnisse Dr. Elten und Sohn was founded in 1938 and was renamed Dreluso Pharmazeutika Dr. Elten & Sohn in 1948, Oldendorf, FRG. Malignancies require a pathological alkaline milieu for growth; the associated increase in oxygen deficiency is caused by an unbalanced diet and carcinogens. GELUM oral-rd restores an optimum milieu and at the same time activates the lymph system, thereby providing the basis for all other tumour therapies. In transplant tumours and in Meth-A mouse fibrosarcoma, only prophylactic administration of GELUM oral-rd lengthened survival time or reduced tumour induction. Lymph node hyperplasia and giant cells in the spleen, occurring only in the pretreated animals, are also interpreted as nonspecific activation of the body's defence system. The clinical investigations are more anecdotal in nature, and the basic documentation and case studies are inadequate. In the prospective, randomized trial in 72 patients suffering from carcinoma of the gastrointestinal tract, the conclusion of efficacy is questionable on account of the incongruence between the group receiving the active drug and the control group. GELUM oral-rd is not registered in Switzerland at the IKS.

Antineoplastic Agents↗
PubMedDate not supplied

Effects of the anti-dementia drug hopantenate calcium upon striatal dopaminergic neurons in young and aged rats.

In the present study we investigated the effects of the anti-dementia drug calcium D-(+)-4-(2,4-dihydroxy-3,3-dimethyl-butyramido) butyrate hemihydrate (hopantenate) on the dopaminergic neurons of rats, and also compared the effects of the drug on dopaminergic neurons in young adult rats (4 months old) and aged rats (21 months old). Hopantenate 1000 mg/kg, p.o. significantly increased striatal dopamine (DA) levels, but displayed almost no effect upon the DOPAC and HVA levels. Furthermore, we investigated the effects of hopantenate upon tyrosine hydroxylase activity by examining NSD-1015-induced L-DOPA accumulation and found that hopantenate 1000 mg/kg, p.o. significantly increased the L-DOPA accumulation. In addition, comparing the effect of hopantenate on dopaminergic neurons in young adult rats and aged rats, we found that the striatal DA, DOPAC and HVA levels were decreased as a concomitant of aging, and hopantenate 1000 mg/kg, p.o. significantly increased DA and DOPAC levels in both ages. The above results clearly indicate that hopantenate enhanced DA biosynthesis by stimulating the activity of tyrosine hydroxylase. Furthermore, the results of hopantenate upon dopaminergic neurons in young adult rats and aged rats suggest that sensitivity to the drug may not be different with age, though the striatal DA, DOPAC and HVA levels of rats were decreased as a concomitant of aging.

3,4-Dihydroxyphenylacetic Acid↗